Development of novel medication strategy and drug efficacy on monocyte lineage cells of a JAK3 inhibitor in rheumatoid arthritis patients
| Project/Area Number |
21591275
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Yoshiya 産業医科大学, 医学部, 教授 (30248562)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | リウマチ学 / 樹状細胞 / サイトカイン / 骨代謝 / 滑膜線維芽細胞 / Jak3 / Jak阻害剤 / 共刺激分子 / 単球系細胞 / 滑膜細胞 |
|---|
| Research Abstract |
In order to evaluate the effect of a Jak3-inhibitor CP690, 550(CP) on rheumatoid arthritis patients, we have focused on monocyte lineage cells, a progenitor for osteoclasts essential for bone resorption and dendritic cells(DCs) that functions as a start point of immune reaction. Differentiation of osteoclasts and DCs were not affected by the addition of CP. Bone resorption of osteoclasts was not affected by CP as well. Although, expression of co-stimulatory molecules on DCs were suppressed and co-culture of lymphocytes resulted in suppressed lymphocyte proliferation and IFN-g production.
|
Report
(4 results)
Research Products
(80 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] JAKインヒビター2010
Author(s)
山岡邦宏
Organizer
第31回日本炎症再生医学会
Place of Presentation
シンポジウム京王プラザホテル(東京)
Year and Date
2010-08-06
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
